ABUS is suddenly cash-relevant because of a Moderna/Genevant settlement receivable, but the core company is still a small clinical-stage HBV developer that must prove imdusiran can move beyond Phase 2a signals.
References
Sources used in this report
SEC issuer filing indexSEC submissions index for Arbutus Biopharma Corporation2026-05-13 · CIK, ticker, exchange, filing inventory, and recent source discovery.SEC company factsSEC XBRL company facts for Arbutus Biopharma Corporation2026-05-13 · Financial cross-checks for revenue, expenses, cash, operating cash flow, assets, liabilities, equity, and shares.Annual reportArbutus FY2025 Form 10-K2026-03-23 · Business model, pipeline, risk factors, Qilu termination, Genevant economics, competition, human capital, and legal proceedings.Quarterly reportArbutus Q1 2026 Form 10-Q2026-05-13 · Q1 2026 financials, settlement receivable, Fast Track disclosure, litigation updates, liquidity, and operating cash flow.Company results releaseArbutus Q1 2026 results release2026-05-13 · Management narrative for Q1 2026 results, cash, settlement economics, imdusiran, and financial tables.Company results releaseArbutus FY2025 results release2026-03-23 · FY2025 revenue, net loss, cash burn, restructuring, Moderna settlement context, and imdusiran functional-cure update.Proxy statementArbutus 2026 definitive proxy statement2026-04-14 · Board, management, share count, incentive plan, Genevant/Roivant related-party disclosure, and governance.Official company product pageArbutus pipeline page2026-05-13 · Official pipeline stage and asset map for imdusiran and AB-101.Government registryClinicalTrials.gov imdusiran registry search2026-05-13 · External registry check for imdusiran studies.Public-health sourceWHO hepatitis B fact sheet2026-05-13 · HBV disease burden, deaths, treatment penetration, and standard care context.Peer quarterly reportAssembly Biosciences Q1 2026 Form 10-Q2026-05-07 · Official peer context for HBV/HDV development and Gilead collaboration.Peer quarterly reportVir Biotechnology Q1 2026 Form 10-Q2026-05-07 · Official peer context for antiviral pipeline competition and balance-sheet scale.